Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia.
AffiliationMédecins Sans Frontières, Phnom Penh, Cambodia. email@example.com
MetadataShow full item record
AbstractOBJECTIVE: Increasing access to highly active antiretroviral therapy to reach all those in need in developing countries (scale up) is slowly expanding to HIV-positive children, but documented experience remains limited. We aimed to describe the clinical, immunologic, and virologic outcomes of pediatric patients with >12 months of highly active antiretroviral therapy in 2 routine programs in Cambodia. METHODS: Between June 2003 and March 2005, 212 children who were younger than 13 years started highly active antiretroviral therapy. Most patients started a standard first-line regimen of lamivudine, stavudine, and nevirapine, using split adult fixed-dosage combinations. CD4 percentage and body weight were monitored routinely. A cross-sectional virologic analysis was conducted in January 2006; genotype resistance testing was performed for patients with a detectable viral load. RESULTS: Mean age of the subjects was 6 years. Median CD4 percentage at baseline was 6. Survival was 92% at 12 months and 91% at 24 months; 13 patients died, and 4 were lost to follow-up. A total of 81% of all patients had an undetectable viral load. Among the patients with a detectable viral load, most mutations were associated with resistance to lamivudine and non-nucleoside reverse-transcriptase inhibitor drugs. Five patients had developed extensive antiretroviral resistance. Being an orphan was found to be a predictor of virologic failure. CONCLUSIONS: This study provides additional evidence of the effectiveness of integrating HIV/AIDS care with highly active antiretroviral therapy for children in a routine setting, with good virologic suppression and immunologic recovery achieved by using split adult fixed-dosage combinations. Viral load monitoring and HIV genotyping are valuable tools for the clinical follow-up of the patients. Orphans should receive careful follow-up and extra support.
- Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
- Authors: Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S
- Issue date: 2007 Oct
- Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
- Authors: Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W
- Issue date: 2007 Feb 1
- Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
- Authors: Gandhi T, Nagappan V, Cinti S, Wei W, Kazanjian P
- Issue date: 2007 Oct 15
- Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
- Authors: Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ
- Issue date: 2007 Jul
- Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
- Authors: Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA
- Issue date: 2005 Sep